Efficacy and prognostic factors of systemic therapies for metastatic adenoid cystic carcinoma.

• DOI: 10.1200/jco.2019.37.15_suppl.e17587
• Publication Date: 2019-05-27T16:11:05Z
• Authors: Cyril Roussel-Sim...; Francois Riet; Geneviève Hervé; Chloe Bertolus; Philippe Maingon; Jean-Philippe Spano; Aurelien Gobert
• Keywords: Adenoid Cystic Carcinoma; Univariate analysis

e17587 Background: Metastatic cystic adenoid carcinoma (mCCA) is a rare entity of cancer associated with poor prognostic. Only limited efficacy data based on case-reports and retrospective analysis are available there currently no standard for treatment. The aim our study to evaluate the prognostic factors in recently diagnosed mCCA. Methods: We retrospectively collected demographic from patients treated mCCA between September 2012 January 2019 at Pitié-Salpêtrière Hospital. Univariate was performed using Cox model. Survival estimated Kaplan-Meier method long rank analysis. Results: Fifteen were included: 8 women 7 men median age diagnosis 57 years (range 32-71). primitive sites accessory salivary glands 9 patients, major 3 lung, cervix lacrimal each other patients. Histology primary tumor 4 cribriform solid types respectively, an intermediate grade 5 high 2 Ki67 35% 8.5-40%). Thirteen received first line therapy, including 10 platinum – LV5FU2, cisplatine anthracycline cyclophosphamide association (CAP) 1 sunitinib. A stable disease found (54%), partial response (31%) had progression evaluation. st PFS 5.8 months 2.0-12.7). With time follow-up 12.9 4.0-61.3), (33%) dead, (53%) still receiving systemic therapy (27%) lines. patient after 6 CAP cycles,received liposomal combined carboplatin cycles 12.7 months. In univariate analysis, statistically significant found. Conclusions: study, efficient mACC 31% rate. Furthermore, here we report duration These preliminary results should be confirmed before becoming new option treatment mACC.